1- Volk WA, Gebhardt B, Hammaskjold M, Kaomer R. Lippincott-Raven, Philadelphia. Medical microbiology. 1995.
2- Steinthorsdottir V, Halldórsson H, Andrésson OS. Clostridium perfringens beta-toxin forms multimeric transmembrane pores in human endothelial cells. Microb pathog. 2000; 28(1): 45-50.
3- McDonel JL. Clostridium perfringens toxins (type a, b, c, d, e). Pharmacology & therapeutics. 1980; 10(3): 617-55.
4- Nilo L. Measurement of biological activities of purified and crude enterotoxin of Clostridium perfringens. Infect.immun. 1975; 12(2): 440-2.
5- Los FC, Randis TM, Aroian RV, Ratner AJ. Role of pore-forming toxins in bacterial infectious diseases. Microbiol Mol Biol. 2013; 77(2): 173-207.
6- Worthington R, Mülders M. The partial purification of Clostridium perfringens beta toxin. OJVR. 1975; 42(3): 91-19.
7- Freedman JC, Theoret JR, Wisniewski JA, Uzal FA, Rood JI, McClane BA. Clostridium perfringens type A–E toxin plasmids. Res Microbiol. 2015; 166(4): 264-79.
8- Navarro MA, McClane BA, Uzal FA. Mechanisms of action and cell death associated with Clostridium perfringens toxins. Toxins. 2018; 10(5): 212.
9- Fang RH, Luk BT, Hu C-MJ, Zhang L. Engineered nanoparticles mimicking cell membranes for toxin neutralization. Adv Drugdeliv Rev. 2015; 90: 69-80.
10- Avgoustakis K. Polylactic-co-glycolic acid (PLGA). Encyclopedia of biomaterials and biomedical engineering. 2005; 1(1): 1-11.
11- Ebrahimi Samani S, Asghari S, Naderimanesh H, Hoseinkhani S. Optimization of Preparation of PEG-PLGA Nanoparticles by Solvent Evaporation Method. Modares J Biotech. 2018; 9(2): 201.
12- Erbetta CDAC, Alves RJ, Magalh J, de Souza Freitas RF, de Sousa RG. Synthesis and characterization of poly (D, L-lactide-co-glycolide) copolymer. 2012.
13- Luk BT, Hu C-MJ, Fang RH, Dehaini D, Carpenter C, Gao W, et al. Interfacial interactions between natural RBC membranes and synthetic polymeric nanoparticles. Nanoscale. 2014; 6(5): 2730-7.
14- Fang RH, Hu C-MJ, Zhang L. Nanoparticles disguised as red blood cells to evade the immune system. Taylor & Francis. 2012.
15- Cavalcanti MTH, Porto T, Porto ALF, Brandi IV, Lima Filho JLd, Pessoa Junior A. Large scale purification of Clostridium perfringens toxins: a review. APSB. 2004; 40(2): 151-64.
16- Sakurai J, Duncan C. Purification of beta-toxin from Clostridium perfringens type C. Infect and immun. 1977; 18(3): 741-5.
17- Coskun O. Separation techniques: chromatography. NCI. 2016; 3(2): 156.
18- Zayerzadeh E, Fardipour A, Jabbari A. A New Purification Method for Beta-Toxin of Clostridium perfringens Type C Vaccinal Strain. J Med Bacteriol. 2014; 3(3-4): 8-13.
19- Xia Q, Zhang Y, Li Z, Hou X, Feng N. Red blood cell membrane-camouflaged nanoparticles: A novel drug delivery system for antitumor application. .APSB. 2019; 9(4): 675-89.